ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer
Crossref DOI link: https://doi.org/10.1186/s12885-016-2923-8
Published Online: 2016-11-18
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Magnusson, Kristina
Gremel, Gabriela
Rydén, Lisa
Pontén, Victor
Uhlén, Mathias
Dimberg, Anna
Jirström, Karin
Pontén, Fredrik
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (SE)
